Abstract
The management of advanced gastronintestinal stromal tumor is increasingly complex because of imatinib refractory disease. Primary resistance to imatinib is uncommon, and most patients progress after development of additional genetic changes. This article reviews management strategies including surgical approaches, local modalities for progressive liver metastases, as well as novel therapeutic agents.
Original language | English (US) |
---|---|
Pages (from-to) | 139-150 |
Number of pages | 12 |
Journal | Hematology/Oncology Clinics of North America |
Volume | 23 |
Issue number | 1 |
DOIs | |
State | Published - Feb 2009 |
Externally published | Yes |
Keywords
- Gastrointestinal stromal tumor
- HSP-90 inhibitors
- IGF-1R
- Nilotinib
- Sorafenib
- Tyrosine kinase inhibitors
ASJC Scopus subject areas
- Hematology
- Oncology